Can you describe what therapeutic drug monitoring means in the context of psychopharmacology—and specifically, why it’s especially important for clozapine?
How have guidelines and real-world practice evolved in recent years regarding clozapine TDM?
Why do you think some clinicians are reluctant to leverage TDM in their practices?
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Explore how clinicians subtype depression using severity, stressors, suicidality, sleep, and anxiety patterns to sharpen diagnosis, guide treatment, and build trust.